Kuriyama Nagato, Ozaki Etsuko, Koyama Teruhide, Matsui Daisuke, Watanabe Isao, Tomida Satomi, Nagamitsu Reo, Hashiguchi Kanae, Inaba Masaaki, Yamada Shinsuke, Horii Motoyuki, Mizuno Shigeto, Yoneda Yutaro, Kurokawa Masao, Kobayashi Daiki, Fukuda Shinpei, Iwasa Koichi, Watanabe Yoshiyuki, Uehara Ritei
Department of Epidemiology for Community Health and Medicine, Kyoto Prefectural University of Medicine, 465 Kajiicho, Kawaramachi-hirokoji, Kamigyo-ku, Kyoto, 602-8566, Japan.
Department of Endocrine and Breast Surgery, Kyoto Prefectural University of Medicine, Kyoto, Japan.
J Bone Miner Metab. 2021 May;39(3):404-415. doi: 10.1007/s00774-020-01160-8. Epub 2020 Oct 12.
Bone mass was recently reported to be related to skeletal muscle mass in humans, and a decrease in cortical bone is a risk factor for osteoporosis. Because circulating myostatin is a factor that primarily controls muscle metabolism, this study examined the role of myostatin in bone mass-skeletal muscle mass interactions.
The subjects were 375 middle-aged community residents with no history of osteoporosis or sarcopenia who participated in a health check-up. Cortical bone thickness and cancellous bone density were measured by ultrasonic bone densitometry in a health check-up survey. The subjects were divided into those with low cortical bone thickness (LCT) or low cancellous bone density (LBD) and those with normal values (NCT/NBD). Bone metabolism markers (TRACP-5b, etc.), skeletal muscle mass, serum myostatin levels, and lifestyle were then compared between the groups.
The percentage of diabetic participants, TRACP-5b, and myostatin levels were significantly higher, and the frequency of physical activity, skeletal muscle mass, grip strength, and leg strength were significantly lower in the LCT group than in the NCT group. The odds ratio (OR) of high myostatin levels in the LCT group compared with the NCT group was significant (OR 2.17) even after adjusting for related factors. Between the low cancellous bone density (LBD) and normal cancellous bone density (NBD) groups, significant differences were observed in the same items as between the LCT and NCT groups, but no significant differences were observed in skeletal muscle mass and blood myostatin levels. The myostatin level was significantly negatively correlated with cortical bone thickness and skeletal muscle mass.
A decrease in cortical bone thickness was associated with a decrease in skeletal muscle mass accompanied by an increase in the blood myostatin level. Blood myostatin may regulate the bone-skeletal muscle relationship and serve as a surrogate marker of bone metabolism, potentially linking muscle mass to bone structure.
最近有报道称，人体骨量与骨骼肌质量有关，皮质骨减少是骨质疏松症的一个危险因素。由于循环中的肌肉生长抑制素是主要控制肌肉代谢的一个因素，本研究探讨了肌肉生长抑制素在骨量与骨骼肌质量相互作用中的作用。
研究对象为375名无骨质疏松症或肌肉减少症病史的中年社区居民，他们参加了一次健康体检。在健康体检调查中，采用超声骨密度测定法测量皮质骨厚度和松质骨密度。将研究对象分为皮质骨厚度低（LCT）或松质骨密度低（LBD）组以及正常值组（NCT/NBD）。然后比较两组之间的骨代谢标志物（TRACP-5b等）、骨骼肌质量、血清肌肉生长抑制素水平和生活方式。
LCT组糖尿病参与者的百分比、TRACP-5b和肌肉生长抑制素水平显著更高，而体力活动频率、骨骼肌质量、握力和腿部力量显著低于NCT组。即使在对相关因素进行调整后，LCT组与NCT组相比，肌肉生长抑制素水平高的优势比（OR）仍具有显著性（OR 2.17）。在低松质骨密度（LBD）组和正常松质骨密度（NBD）组之间，与LCT组和NCT组之间相同的项目存在显著差异，但骨骼肌质量和血液肌肉生长抑制素水平未观察到显著差异。肌肉生长抑制素水平与皮质骨厚度和骨骼肌质量显著负相关。
皮质骨厚度降低与骨骼肌质量减少有关，同时血液中肌肉生长抑制素水平升高。血液中的肌肉生长抑制素可能调节骨与骨骼肌的关系，并作为骨代谢的替代标志物，潜在地将肌肉质量与骨结构联系起来。
